Close Menu

NEW YORK – Pacific Biosciences on Monday said that it expects to report fourth quarter revenues of around $27 million, representing a sequential quarterly increase of 41 percent but a slight decline from the $27.9 million revenues reported for Q4 2019.

The preliminary revenues surpass the consensus Wall Street estimate for revenues of $23.7 million. Despite the beat, in early Monday trade on the Nasdaq, shares of PacBio were down around 3 percent at $33.51

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.